Trial Profile
Randomized Clinical Trial to Study Pharmacological Cardioversion of Paroxysmal Atrial Fibrillation by Vernakalant and Flecainide
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Aug 2023
Price :
$35
*
At a glance
- Drugs Flecainide (Primary) ; Vernakalant (Primary)
- Indications Paroxysmal atrial fibrillation
- Focus Therapeutic Use
- Acronyms SELECTCARFAP
- 04 Aug 2023 Status changed from recruiting to completed.
- 05 Mar 2023 Planned End Date changed from 1 Jun 2023 to 1 Sep 2023.
- 05 Mar 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Jun 2023.